Considering COVID impact the Co has made good progress and HF is establishing in next 6 months.
Re conf call:
Sounds like reimbursement is moving forward with medicare provisional payments going through regularly.
McKessons is still in trial mode but the barrier to uptake is now only clinical acceptance by individual sites.
Was excited by the higher testing rate for HF monitoring and that step change in TAM for that. HF for oncology seemed to be the stepping point but the larger HF market may be accessible with the data from oncology-related HF study opportunity. The Hf commercialization is the next area to watch.
Interesting that AU Gov support was an additional help in last 3 months.
Sounds like SaaS sales have had to become capital-light for some customers with limited capex budgets. The ARR is more important and higher revenues from that may be offset by capital amortization requirements.
All IMHO and DYOR
- Forums
- ASX - By Stock
- IPD
- Ann: Appendix 4C - Quarter ended 30 June 2020
IPD
impedimed limited
Add to My Watchlist
7.69%
!
3.6¢

Ann: Appendix 4C - Quarter ended 30 June 2020, page-3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
3.6¢ |
Change
-0.003(7.69%) |
Mkt cap ! $72.98M |
Open | High | Low | Value | Volume |
3.7¢ | 3.7¢ | 3.6¢ | $7.151K | 194.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 109660 | 3.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.7¢ | 42471 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9660 | 0.036 |
2 | 390000 | 0.035 |
3 | 338208 | 0.034 |
1 | 638321 | 0.033 |
3 | 459150 | 0.030 |
Price($) | Vol. | No. |
---|---|---|
0.039 | 865746 | 2 |
0.040 | 577500 | 3 |
0.041 | 350000 | 1 |
0.042 | 138405 | 2 |
0.043 | 196890 | 3 |
Last trade - 15.29pm 04/07/2025 (20 minute delay) ? |
Featured News
IPD (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online